Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease

C. L. Chen, W. C. Orr, M. H. Verlinden, A. Dettmer, H. Brinkhoff, D. Riff, S. Schwartz, R. D. Soloway, R. Krause, F. Lanza, R. J. Mack

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: ABT-229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats. Aim: To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease. Methods: In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. The efficacy was evaluated by Patient Symptom Questionnaire, daily diary, endoscopy and global evaluation of efficacy. Results: There were no statistically significant improvement scores for any of the ABT-229 treatment groups vs. the placebo group in any of the efficacy parameters. Reflux symptom scores were significantly worse after treatment in the dyspeptic group. ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg. Conclusion: ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease.

Original languageEnglish (US)
Pages (from-to)749-757
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Esophageal Diseases
Gastroesophageal Reflux
Placebos
Therapeutics
Motilin
Heartburn
Lower Esophageal Sphincter
Gastric Emptying
Patient Safety
Double-Blind Method
Endoscopy
Multicenter Studies
Alemcinal
motilin receptor
Cats
Anti-Bacterial Agents
Pressure

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. / Chen, C. L.; Orr, W. C.; Verlinden, M. H.; Dettmer, A.; Brinkhoff, H.; Riff, D.; Schwartz, S.; Soloway, R. D.; Krause, R.; Lanza, F.; Mack, R. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 4, 2002, p. 749-757.

Research output: Contribution to journalArticle

Chen, CL, Orr, WC, Verlinden, MH, Dettmer, A, Brinkhoff, H, Riff, D, Schwartz, S, Soloway, RD, Krause, R, Lanza, F & Mack, RJ 2002, 'Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease', Alimentary Pharmacology and Therapeutics, vol. 16, no. 4, pp. 749-757. https://doi.org/10.1046/j.1365-2036.2002.01218.x
Chen, C. L. ; Orr, W. C. ; Verlinden, M. H. ; Dettmer, A. ; Brinkhoff, H. ; Riff, D. ; Schwartz, S. ; Soloway, R. D. ; Krause, R. ; Lanza, F. ; Mack, R. J. / Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. In: Alimentary Pharmacology and Therapeutics. 2002 ; Vol. 16, No. 4. pp. 749-757.
@article{0acc940ae23a4b8c8861b90c944978c3,
title = "Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease",
abstract = "Background: ABT-229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats. Aim: To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease. Methods: In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. The efficacy was evaluated by Patient Symptom Questionnaire, daily diary, endoscopy and global evaluation of efficacy. Results: There were no statistically significant improvement scores for any of the ABT-229 treatment groups vs. the placebo group in any of the efficacy parameters. Reflux symptom scores were significantly worse after treatment in the dyspeptic group. ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg. Conclusion: ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease.",
author = "Chen, {C. L.} and Orr, {W. C.} and Verlinden, {M. H.} and A. Dettmer and H. Brinkhoff and D. Riff and S. Schwartz and Soloway, {R. D.} and R. Krause and F. Lanza and Mack, {R. J.}",
year = "2002",
doi = "10.1046/j.1365-2036.2002.01218.x",
language = "English (US)",
volume = "16",
pages = "749--757",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease

AU - Chen, C. L.

AU - Orr, W. C.

AU - Verlinden, M. H.

AU - Dettmer, A.

AU - Brinkhoff, H.

AU - Riff, D.

AU - Schwartz, S.

AU - Soloway, R. D.

AU - Krause, R.

AU - Lanza, F.

AU - Mack, R. J.

PY - 2002

Y1 - 2002

N2 - Background: ABT-229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats. Aim: To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease. Methods: In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. The efficacy was evaluated by Patient Symptom Questionnaire, daily diary, endoscopy and global evaluation of efficacy. Results: There were no statistically significant improvement scores for any of the ABT-229 treatment groups vs. the placebo group in any of the efficacy parameters. Reflux symptom scores were significantly worse after treatment in the dyspeptic group. ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg. Conclusion: ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease.

AB - Background: ABT-229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats. Aim: To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease. Methods: In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. The efficacy was evaluated by Patient Symptom Questionnaire, daily diary, endoscopy and global evaluation of efficacy. Results: There were no statistically significant improvement scores for any of the ABT-229 treatment groups vs. the placebo group in any of the efficacy parameters. Reflux symptom scores were significantly worse after treatment in the dyspeptic group. ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg. Conclusion: ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease.

UR - http://www.scopus.com/inward/record.url?scp=0036109729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036109729&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01218.x

DO - 10.1046/j.1365-2036.2002.01218.x

M3 - Article

C2 - 11929393

AN - SCOPUS:0036109729

VL - 16

SP - 749

EP - 757

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -